For each species, average MIC to particular drug can be determined. from MIC analysis, C. krusei is intrinsically more resistant to azole drugs than C. albicans. Intrinsic resistance of C. krusei and C. glabrata to azole drugs resulted in an increased frequency of resistant species in population. Azole drugs used, suppress the growth of sensitive C. albicans but allow the growth of more resistant strains or species.
(ii) Change to More Resistant Strain: Azole sensitive and resistant isolates obtained from AIDS patients and analyzed by pulsed-field gel electrophoresis (molecular karyotyping) and restriction fragment length polymorphism (RFLP). The sensitive and resistant isolates differed by RFLP but not by karyotyping.
(iii) Genetic alterations that render a strain resistant: Strain resistant, exposure to the drug over long period of time and sensitive strain can become resistance. It is hypothesized that the drug itself does not cause resistance, and selects more resistant cells in the population. Genetic mutation occurs in all organisms at a low frequency. Under selective drug pressure specific random mutations that render the cell slightly more resistant dominant strain in the population. 
(iv) Alteration in other enzymes in the Ergosterol biosynthetic pathway: Another common mechanism of drug resistance is modification of the target enzyme and/or other enzymes in the same biochemical pathway, modifications in the ergosterol pathway are likely to generate resistance not only to the drug to which the cells are exposed but also to related drugs. Plasmid complementation of the ERG3 mutation in S. cerevisiae suggests that the ERG3 mutation alone can cause azole resistance.
Eukaryotic cells contain two types of efflux pumps that are known to contribute to drug resistance: (I) Adenosine triphosphate (ATP) -binding cassette transporters (ABCT) family (II) Major facilitators (MF) family I) ABCT family
The ABCT are composed of four protein domains: two membrane-spanning domains (MSD), each consisting of six or seven transmembrane-spanning segments, and two nucleotide binding domains (NBD). The NBD of ABCT bind ATP through an ABC that consists of several conserved peptide motifs, including two Walker domains, a Signature domain and a Center domain. The ATP that is bound to the ABC is used as a source of energy for the ABCT, although the mechanism by which the ATP energy causes transport of the substrate molecule is unknown.
Candida drug resistant (CDR) gene is found to be associated with azole based drug resistance. Level of CDR were higher in clinical azole resistance isolates than those in clinical susceptible ones, a deletion of CDR results in azole hyper susceptibility to azole drugs The MF does not contain NBD. They are composed primarily of 12 to 14 transmembrane segments (110, 140). The MF use the proton motive force of the membrane (gradient of H1across the membrane) as a source of energy. MDR is the only MF gene reported having correlation with drug resistance 2) Non Azole resistance i) Allylamine and thiocarbamate resistance: Resistance to Allylamine and thiocarbamates has not been reported, although resistant strains have been described for S. cerevisiae. Prolonged use will probably select for strain replacement with a resistant isolate or the development of secondary resistance in the original sensitive isolate (Anaissie et al., 1989) .
(ii) 5-Flucytosine resistance: Primary or intrinsic resistance to 5-FC -common phenomenon 10% clinical isolates of C. albicans are intrinsically resistant and that of 30% will develop secondary resistance (Anaissie et al., 1989) . Cryptococcus neoformans mutations are the most likely cause of 5-FC resistance in these yeasts, analysis of two genetic loci, FCY1 and FCY2 that can be mutated to produce 5-FC resistance.
Primary or intrinsic resistance to 5-FC is usually the result of a defect in cytosine deaminase and secondary resistance to 5-FC in C. albicans is due primarily to a decrease in the activity of the uracil phosphoribosyl transferase (UPRTase), which is involved in the synthesis of FUMP and FdUMP. Of the two serotypes of C. albicans, serotype B is more frequently associated with 5-FC resistance.
Incidence of Antifungal resistance in Veterinary and Medical field
There are few reported incidences on antifungal resistance both in Veterinary and medical field. Some of them are highlighted here. Jadhav, (2001) Due to drug-resistant fungi, oropharyngeal Candidasis is a major problem for patients infected with Human immunodeficiency virus. Alteration in immune status associated with the AIDS epidemic, cancer chemotherapy, organ and bone marrow transplantation may be responsible to antifungal drugs resistance (White et al., 1998) . Drug resistant strains of Candida albicans flared up in oral cavities during late stages of AIDS patients after antifungal drug therapy.
Prevention and control of antifungal resistance
Strategies to avoid and suppress the emergence of antifungal resistance have not been defined, approaches recommended for antibacterial resistance could be suggested, these includes, (i) Prudent use of antifungal drugs (ii) FAppropriate dosing with special emphasis on avoiding treatment with low antifungal dosage (iii) Therapy with combinations of existing drugs (iv) Treatment with the appropriate antifungal drugs (v) Use of surveillance studies to determine the true frequency of antifungal drug resistance
Conclusions
There was no predominant mechanism contributing to resistance of antifungal drugs. Unlike resistance to antibiotics, antifungal drug resistance due to plasmid mediated mechanism has not been reported. With increased usage of different antifungal drugs, we may expect an increasing number of clinical fungal pathogens becoming resistance to these drugs. Cellular and molecular factors contribute to anti fungal drug resistance. Rapid identification of fungal pathogens and the measurement of the MIC of clinical isolates in vitro will be helpful. Future Prospects: The mechanism by which the different factors that contribute to overall antifungal drug resistance is still in infancy stage. There is a need for considering several variables to minimize the risk for development of resistance. There is a clear need for the next generation of antifungal agents. The ongoing developments in the understanding of resistance will assist in the development of diagnostic strategies to identify resistant clinical isolates. Commonly used antifungal drugs are ergosterol biosynthesis inhibitors, polyenes, and 5-flucytosine (5-FC). In a resistant cell, the azoles are blocked from interacting normally with the target enzyme because the enzyme can be modified and/or overexpressed. With increased usage of different antifungal drugs, we may expect an increasing number of clinical fungal pathogens becoming resistant to these agents (Cohen, 1992) .
